VYNE Therapeutics

VYNE Therapeutics

VYNE Therapeutics was incorporated in 2016 as Menlo Therapeutics, later merging with Foamix Pharmaceuticals to create a specialty dermatology company with a foothold in both acne and rosacea treatments. After the commercial-stage acne franchise was sold to Cutia Therapeutics in 2022, CEO David Domzalski refocused the remaining pipeline on novel anti-inflammatory therapies, positioning the firm as a clinical-stage biotechnology company rather than a commercial dermatology player. The company's lead asset is VYN202, a BET inhibitor formulated as a topical gel. BET inhibitors are a class of molecules that target bromodomain and extraterminal domain proteins to regulate gene expression in inflammatory pathways. VYNE's approach aims to deliver this mechanism directly to the skin, seeking to suppress the myofibroblast activation that drives fibrosis in conditions such as hypertrophic scars and systemic sclerosis. The platform also includes sublingual delivery candidates targeting autoimmune disorders, though the topical dermatology applications remain the priority. The geographic focus is the United States, with regulatory and clinical operations concentrated in New Jersey. Since the asset sale in 2022, VYNE has operated as a lean, development-stage company with a small team dedicated to advancing VYN202 through preclinical and Phase 1 trials. In October 2024, the company reported positive preclinical data for VYN202 in models of skin fibrosis (per the firm's official communications, October 2024). The firm trades on Nasdaq under the symbol VYNE and maintains no disclosed philanthropic or adjacent investment vehicles. Its operating model is that of a publicly traded biotech reliant on equity and milestone-based financing rather than an evergreen family-office or asset-management structure. VYNE's structural differentiator is its chemistry-driven approach to localized BET inhibition. While most companies in the BET inhibitor space pursue oncology applications through systemic oral dosing, VYNE aims to sidestep systemic toxicity by applying the molecule topically to inflamed skin. This reduces the safety burden and opens a path to treating chronic, non-fatal dermatologic conditions that large pharmaceutical companies often overlook. The company's pivot from commercial dermatology to a single-platform drug-development engine makes it a concentrated bet on a specific mechanism translated into a topical formulation.